]]><\/p>\n
ENR AT-A-GLANCE
\n5 Things to Know<\/p>\n
EXPAND \u2193
\nCOLLAPSE \u2191<\/p>\n
$800M-PLUS EXPANSION<\/p>\n
GSK plans to expand its biopharmaceutical manufacturing campus in Upper Merion Township, Pa., with construction scheduled to begin in 2027.<\/p>\n
FOUR FACILITY COMPONENTS<\/p>\n
Following demolition of existing buildings, plans call for a commercial-scale biologics manufacturing facility, R&D pilot plant, centralized quality-control laboratory and manufacturing science and technology hub.<\/p>\n
2030 OPERATIONS TARGET<\/p>\n
Company officials say the expanded campus should be fully operational by 2030 and create more than 300 permanent jobs within five years.<\/p>\n
2027 CONSTRUCTION START<\/p>\n
GSK expected construction of its Upper Merion biologics \u201cflex\u201d factory to begin in 2026 when it announced the project in 2025; the latest plan places the start in 2027.<\/p>\n
$1.7B IN PENNSYLVANIA<\/p>\n
The Upper Merion investment and GSK\u2019s separate $800-million Marietta manufacturing project total nearly $1.7 billion in Pennsylvania.<\/p>\n
\nCOLLAPSE AT-A-GLANCE \u2191\n<\/p>\n
GSK detailed plans Oct. 9<\/a> for a more than $800-million expansion of its biopharmaceutical manufacturing campus in Upper Merion Township, Pa., with construction scheduled to begin in 2027.<\/p>\n Demolition of existing buildings will make way for a commercial-scale biologics manufacturing facility that can support clinical and commercial drug production, state officials said. Plans also include a co-located research and development pilot plant, a centralized quality-control laboratory and a manufacturing science and technology hub.<\/p>\n Company officials said the expanded campus should fully operate by 2030 and create more than 300 permanent jobs within five years.<\/p>\n Plans for the biologics factory date to September 2025<\/a>, when GSK, the name change from GlaxoSmithKline made in 2022, included the project in $1.2 billion of U.S. manufacturing and technology investments. The London-based manufacturer then expected construction of the Upper Merion “flex” factory to begin in 2026; the latest announcement places the start in 2027.<\/p>\n “We are going to need about 300, or north of 300, new full-time GSK employees to run this state-of-the-art facility, and that doesn’t include all the trades that we need to build this actual plant,” GSK Upper Merion site director John Jewett told KYW Newsradio<\/a>.<\/p>\n Commercial production, research and development and advanced digital capabilities are planned together at the Upper Merion campus. The previously announced flex factory is designed to support potential medicines targeting respiratory diseases, including chronic obstructive pulmonary disease and asthma, as well as several forms of cancer.<\/p>\n \u201cInvesting in additional commercial and R&D manufacturing with advanced digital capabilities at our Upper Merion site will help accelerate the development and supply of future medicines for patients,\u201d GSK Global Supply Chain President Regis Simard said.<\/p>\n